SEOM clinical guideline for treatment of kidney cancer (2019)

Lázaro-Quintela, Martín; Valderrama, Begoña P.; Suárez, Cristina; Velasco, Guillermo de; Beato, Carmen; Chirivella, Isabel; González-del-Alba, Aranzazu; Laínez, Núria; Mendez-Vidal, María José; Arranz, José Ángel

doi:10.1007/s12094-019-02285-7

“…The indication with the greatest number of candidates receiving bevacizumab was mCRC (5653 patients), and the one with the fewest recipients was mRCC (31 patients) (table 1). Non-microcytic (85.0%) 25 Adenocarcinoma (63.8%) 26 Renal cell carcinoma (85.0%) 27 Epithelial ovarian (90.0%) 28…”

Section: Resultsmentioning

confidence: 99%

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

Calleja

¹

,

Albanell

²

,

Aranda

³

et al. 2021

Eur J Hosp Pharm

11

0

View full text Add to dashboard Cite

Objective To assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. Methods A 3-year budget impact analysis model was adapted to estimate the cost of introducing biosimilars of bevacizumab in the SNHS for the adult population who were candidates to receive treatment with bevacizumab. Values for the estimation of the population were obtained from the literature and were validated by an expert panel. In this analysis only pharmaceutical costs (€, year 2021) obtained from official databases were considered. A sensitivity analysis was performed to examine the robustness of the model. Results The introduction of bevacizumab biosimilars would generate an annual cost saving of €11 558 268 (−5.1%) for the first year with a penetration share of biosimilars from 30.0%, €29 126 373 (−8.5%) for the second year with a share of 50.0% and €52 361 778 (−13.6%) for the third year with a share of 80.0%. The total pharmaceutical costs of the scenario without biosimilars are €227 033 352 for the first year, €342 663 209 for the second year and €385 013 076 for the third year. In contrast, the pharmaceutical costs of the scenario with bevacizumab biosimilars are €215 475 084, €313 536 836 and €332 651 297 for years 1, 2 and 3, respectively. Conclusions The introduction of biosimilars in the Spanish Health System would generate saving costs in the pharmacological budget to boost biological drugs from the first year.

show abstract

“…RCCs arise from a variety of specialized cells located along the length of the nephron, giving rise to the diversity of histologic RCC types (3). The most common type of RCC is clear-cell RCC, that accounts for up to 75% of RCCs (4).…”

Section: Introductionmentioning

confidence: 99%

“…About 65% of patients with RCC have localized tumors, which are generally treated with surgery and may be cured by total or partial nephrectomy (1,4). However, the remaining ~35% of patients who present with advanced RCC (aRCC) (which can be partially resected or destructed by surgery) or patients who relapse after local therapy, typically require systemic treatment (1,5,6).…”

Section: Introductionmentioning

confidence: 99%

Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists

Fernández

¹

,

Lázaro-Quintela

²

,

Crespo

³

et al. 2022

View full text Add to dashboard Cite

IntroductionThe purpose of this investigation was to explore patients’ and oncologists’ preferences for the characteristics of a pharmacological regimen for patients with advanced renal cell carcinoma (aRCC).Material and MethodsCross-sectional observational study based on a discrete choice experiment (DCE) conducted in Spain. A literature review, a focus group with oncologists and interviews with patients informed the DCE design. Five attributes were included: progression survival gain, risk of serious adverse events (SAEs), health-related quality of life (HRQoL), administration mode, and treatment cost. Preferences were analyzed using a mixed-logit model to estimate relative importance (RI) of attributes (importance of an attribute in relation to all others), which was compared between aRCC patients and oncologists treating aRCC. Willingness to pay (WTP, payer: health system) for a benefit in survival or in risk reduction and maximum acceptable risk (MAR) in SAEs for improving survival were estimated from the DCE. Subgroup analyses were performed to identify factors that influence preference.ResultsA total of 105 patients with aRCC (77.1% male, mean age 65.9 years [SD: 10.4], mean time since RCC diagnosis 6.3 years [SD: 6.1]) and 67 oncologists (52.2% male, mean age 41.9 years [SD: 8.4], mean duration of experience in RCC 10.2 years [SD: 7.5]) participated in the study. The most important attribute for patients and oncologists was survival gain (RI: 43.6% vs. 54.7% respectively, p<0.05), followed by HRQoL (RI: 35.5% vs. 18.0%, respectively, p<0.05). MAR for SAEs was higher among oncologists than patients, while WTP (for the health system) was higher for patients. Differences in preferences were found according to time since diagnosis and education level (patients) or length of professional experience (oncologists).ConclusionPatients’ and oncologists’ preferences for aRCC treatment are determined mainly by the efficacy (survival gain) but also by the HRQoL provided. The results of the study can help to inform decision-making in the selection of appropriate aRCC treatment.

show abstract

“…Renal cell carcinoma (RCC) is one of the most lethal urological malignancies. Currently, novel cases of RCC have skyrocketed worldwide with approximately 400,000 cases emerging each year [ 1 ]. Kidney renal clear cell carcinoma (KIRC) is considered the most aggressive histological type, accounting for 70–80% of all RCC cases [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Upregulated Transcription Factor PITX1 Predicts Poor Prognosis in Kidney Renal Clear Cell Carcinoma-Based Bioinformatic Analysis and Experimental Verification

Zhang

¹

,

Zhang

²

,

Zhang

³

et al. 2021

View full text Add to dashboard Cite

Paired-like homeodomain transcription factor 1 (PITX1) is involved in numerous biological processes, including cell growth, progression, and invasion in various malignant tumors. Nevertheless, the relationship between PITX1 and kidney renal clear cell carcinoma (KIRC) remains unclear. The clinical role and functions of PITX1 were analyzed by integrating multiple open-access online datasets. Further experimental verification was performed via quantitative real-time PCR (qRT-PCR) to detect the expression of PITX1 in 10 pairs of KIRC tissues. Our results revealed that PITX1 mRNA was overexpressed in tumor tissues compared with normal tissues in the TCGA-KIRC database ( p < 0.001 ) and numerous independent cohorts ( p < 0.05 ). Further, high expression of PITX1 mRNA was detected in KIRC tissues compared with adjacent normal tissues in our center by qRT-PCR ( N = 10 , p < 0.05 ). Logistic regression analysis demonstrated that the PITX1 level was positively associated with KIRC patients, T and M stages, histologic grade, and pathologic stage (all p < 0.05 ). Survival analysis showed that upregulation of PITX1 mRNA was associated with poor overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) (all p < 0.05 ). Univariate/multivariate Cox hazard regression analysis revealed that PITX1 was an independent risk factor for OS in patients with KIRC ( HR = 1.998 , p = 0.003 ). Accordingly, the time-independent receiver operating characteristic (ROC) curve confirmed that PITX1 had good predictive efficacy for OS and DSS. Meanwhile, a prediction model constructed by nomogram was used to predict the OS of KIRC patients, and the calibration plot indicated this model shows high accuracy. We also revealed some downstream target genes of PITX1-related signaling pathways. Our finding suggested that high PITX1 mRNA expression may act as an independent predictive factor of poor prognosis in patients with KIRC. The prognostic model based on the nomogram would be instrumental in evaluating the survival rate in KIRC patients.

show abstract

SEOM clinical guideline for treatment of kidney cancer (2019)

Cited by 20 publications

References 77 publications

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists

Upregulated Transcription Factor PITX1 Predicts Poor Prognosis in Kidney Renal Clear Cell Carcinoma-Based Bioinformatic Analysis and Experimental Verification

Contact Info

Product

Resources

About